» Articles » PMID: 36411483

Evaluation of Tumor-infiltrating Lymphocytes (TILs) in Molecular Subtypes of an Indian Cohort of Breast Cancer Patients

Abstract

Objectives: Evaluation of tumor-infiltrating lymphocytes (TILs) distribution in an Indian cohort of breast cancer patients for its prognostic significance.

Methods: A retrospective cohort of breast cancer patients from a single onco-surgeon's breast cancer clinic with a uniform treatment strategy was evaluated for TILs. Tumor sections were H&E stained and scored for the spatial distribution and percent stromal TILs infiltration by a certified pathologist. The scores were analysed for association with treatment response and survival outcomes across molecular subtypes.

Results: Total 229 breast cancer tumors were evaluated. Within spatial distribution categories, intra-tumoral TILs were observed to be associated with complete pathological response and lower recurrence frequency for the entire cohort. Subtype-wise analysis of stromal TILs (sTILs) re-enforced significantly higher infiltration in TNBC compared to HER2-positive and ER-positive tumors. A favourable association of higher stromal infiltration was observed with treatment response and disease outcomes, specifically in TNBC.

Conclusion: Intra-tumoral TILs showed a higher proportion with favourable association with better patient outcomes in an Indian cohort, unlike western cohorts where both stromal and intra-tumoral TILs show similar association with prognosis. With further validation, TILs can be developed as a cost-effective surrogate marker for treatment response, especially in a low-resource setting such as India.

Citing Articles

CD3+ Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Their Prognostic Role and Association With Clinical Parameters.

Chauhan R, Patil V Cureus. 2025; 16(12):e75479.

PMID: 39791074 PMC: 11717322. DOI: 10.7759/cureus.75479.


Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram.

Tan C, Xu J, Zhang S, Liu S, Yang X, Wu D Breast Cancer (Dove Med Press). 2024; 16:705-723.

PMID: 39464238 PMC: 11505482. DOI: 10.2147/BCTT.S484055.


Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.

de Moraes F, Cavalcanti Souza M, Sano V, Moraes R, Melo A Clin Transl Oncol. 2024; .

PMID: 39154313 DOI: 10.1007/s12094-024-03661-8.


HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?.

Baez-Navarro X, van den Ende N, Nguyen A, Sinke R, Westenend P, van Brakel J Breast Cancer Res. 2024; 26(1):41.

PMID: 38468323 PMC: 10926638. DOI: 10.1186/s13058-024-01783-z.

References
1.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

2.
Sharma P, Lopez-Tarruella S, Garcia-Saenz J, Khan Q, Gomez H, Prat A . Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res. 2018; 24(23):5820-5829. PMC: 6279513. DOI: 10.1158/1078-0432.CCR-18-0585. View

3.
El Bairi K, Haynes H, Blackley E, Fineberg S, Shear J, Turner S . The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021; 7(1):150. PMC: 8636568. DOI: 10.1038/s41523-021-00346-1. View

4.
Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

5.
Gruosso T, Gigoux M, Manem V, Bertos N, Zuo D, Perlitch I . Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019; 129(4):1785-1800. PMC: 6436884. DOI: 10.1172/JCI96313. View